サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1529630

細胞出発材料の市場規模、シェア、動向分析レポート：製品別、グレード別、最終用途別、地域別、セグメント予測、2024年～2030年

Cellular Starting Materials Market Size, Share & Trends Analysis Report By Product (Leukopaks, Cells & Tissues), By Grade (GMP, Research-use), By End U-use, By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.40円
細胞出発材料の市場規模、シェア、動向分析レポート：製品別、グレード別、最終用途別、地域別、セグメント予測、2024年～2030年
出版日: 2024年07月03日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

細胞出発材料市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の細胞出発材料市場規模は2030年までに48億4,000万米ドルに達すると予測され、2024年から2030年にかけて22.74％のCAGRで拡大すると予測されています。

がん、糖尿病、自己免疫疾患などの慢性疾患の有病率の増加、投資の増加、細胞および遺伝子ベースの治療に対する需要の増加、技術革新は、予測期間にわたって細胞出発材料市場を強化すると予想されています。

細胞出発物質は、細胞療法や遺伝子療法の開発をサポートする上で重要な役割を果たしています。これらは自己細胞療法と同種細胞療法の両方に不可欠です。細胞治療の分野が急速に拡大し続けるにつれ、高品質のヒト細胞出発材料に対する需要が増加しています。細胞を用いた治療は、がん、神経変性疾患、自己免疫疾患など様々な疾患に対して研究されており、様々な種類の出発材料に対する需要が増加しています。さらに、バイオプロセス技術、細胞培養技術、品質管理措置の継続的な進歩により、細胞出発物質の製造効率と拡張性が向上し、企業は製品の品質と一貫性を維持しながら、これらの物質に対する需要の増加に対応できるようになっています。

COVID-19パンデミックは、サプライチェーンや製造工程の混乱が供給不足や製造スケジュールの遅れにつながり、市場に大きな影響を与えました。自家細胞療法の場合、患者由来の細胞を出発材料として使用するため、パンデミックによって患者の収集期間が延長されました。しかし、パンデミックは細胞ベースの治療の重要性を浮き彫りにし、この分野への投資の増加や一部の治療に対する規制当局の承認促進にもつながった。

しかし、細胞治療に関連する厳しい規制は、細胞出発材料市場にとって大きな課題となっています。こうした規制は、細胞・遺伝子治療製品の製造コストや出発原料の入手コストを上昇させる。世界中の様々な地域が、細胞治療用の細胞出発材料の収集、加工、使用に関する特定の規制を設けています。21 CFR 1271.10（a）に概説されている特定の基準を満たす細胞治療製品は、米国公衆衛生法361条に基づき、ヒト細胞、組織、細胞・組織由来製品（HCT/Ps）としてのみ規制されています。

細胞出発材料市場レポートハイライト

  • 2023年、ロイコパックは市場シェア70.80%で製品セグメントを独占。
  • 2023年には、GMPがグレード別セグメントで優位を占め、収益で最大の市場シェアを占め、予測期間には22.78%のCAGRで最も高い成長が見込まれます。
  • 製薬・バイオテクノロジー企業は、2023年に51.04%の最大シェアを占め、最終用途市場を独占しました。これは、新規治療を市場に投入するための研究開発に多額の投資を行い、製造プロセスの主要成分として細胞出発物質を活用していることが背景にあります。
  • 最終用途別では、CMOとCROのセグメントが、高度な研究と製造技術への投資の増加により、最も速いCAGRで成長すると予測されています。
  • 北米地域は、研究開発活動への投資の増加、細胞ベースの治療に対する需要の高まり、先進的なヘルスケアインフラなどの要因により、43.49%のシェアで細胞出発材料市場を独占しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 細胞出発材料市場の変数、動向、範囲

  • 市場系統の見通し
  • 市場力学
  • 細胞出発材料市場分析ツール

第4章 細胞出発材料市場：製品別推定・動向分析

  • セグメントダッシュボード
  • 世界の細胞出発材料市場の製品別変動分析
  • 世界の細胞出発材料市場規模と動向分析、製品別、2018年-2030年
  • ロイコパック
  • 細胞と組織

第5章 細胞出発材料市場：グレード別推定・動向分析

  • セグメントダッシュボード
  • 世界の細胞出発材料市場のグレード別変動分析
  • 世界の細胞出発材料市場の規模と動向分析、グレード別、2018年-2030年
  • GMP
  • 研究

第6章 細胞出発材料市場：最終用途別推定・動向分析

  • セグメントダッシュボード
  • 世界の細胞出発材料市場の最終用途別変動分析
  • 世界の細胞出発材料市場の規模と動向分析、最終用途別、2018年-2030年
  • 製薬・バイオテクノロジー企業
  • CMOとCRO
  • 学術研究機関

第7章 細胞出発材料市場：地域別推定・動向分析

  • 地域別市場シェア分析、2023年および2030年
  • 地域別市場ダッシュボード
  • 市場規模、予測動向分析、2018年-2030年
  • 北米
    • 北米市場推計・予測、2018年-2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 欧州市場推計・予測、2018年-2030年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • アジア太平洋市場推計・予測、2018年-2030年
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ラテンアメリカ市場推計・予測、2018年-2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 中東・アフリカ市場推計・予測、2018年-2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 企業/競合の分類
  • 戦略マッピング
  • 企業市況分析、2023年
  • 企業プロファイル/上場企業
    • AllCells
    • Charles River Laboratories
    • BioIVT
    • NMDP BioTherapies
    • CGT GLOBAL
    • Excellos
    • Anthony Nolan
    • STEMCELL Technologies
    • HumanCells Bio
    • AcceGen
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Global cellular starting materials market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 4 Global cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 5 Global cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America cellular starting materials market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 8 North America cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 9 North America cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 10 U.S. cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 11 U.S. cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 12 U.S. cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 13 Canada cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 14 Canada cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 15 Canada cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Mexico cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 17 Mexico cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 18 Mexico cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe cellular starting materials market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 21 Europe cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 22 Europe cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 23 Germany cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 24 Germany cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 25 Germany cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 26 UK cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 27 UK cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 28 UK cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 29 France cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 30 France cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 31 France cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Italy cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 33 Italy cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 34 Italy cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Spain cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 36 Spain cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 37 Spain cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 38 Denmark cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 39 Denmark cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 40 Denmark cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Sweden cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 42 Sweden cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 43 Sweden cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Norway cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 45 Norway cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 46 Norway cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific cellular starting materials market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 51 China cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 52 China cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 53 China cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Japan cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 55 Japan cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 56 Japan cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 57 India cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 58 India cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 59 India cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 60 South Korea cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 61 South Korea cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 62 South Korea cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 63 Australia cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 64 Australia cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 65 Australia cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Thailand cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 67 Thailand cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 68 Thailand cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Latin America cellular starting materials market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 71 Latin America cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 72 Latin America cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 73 Brazil cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 74 Brazil cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 75 Brazil cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 76 Argentina cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 77 Argentina cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 78 Argentina cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 79 MEA cellular starting materials market, by country, 2018 - 2030 (USD Million)
  • Table 80 MEA cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 81 MEA cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 82 MEA cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 83 South Africa cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 84 South Africa cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 85 South Africa cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 89 UAE cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 90 UAE cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 91 UAE cellular starting materials market, by end use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait cellular starting materials market, by product, 2018 - 2030 (USD Million)
  • Table 93 Kuwait cellular starting materials market, by grade, 2018 - 2030 (USD Million)
  • Table 94 Kuwait cellular starting materials market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 Cellular Starting Materials market: Market outlook
  • Fig. 5 Cellular Starting Materials market: Segment outlook
  • Fig. 6 Cellular Starting Materials market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 Cellular starting materials market driver impact
  • Fig. 9 Cellular starting materials market restraint impact
  • Fig. 10 Cellular starting materials market: Product outlook and key takeaways
  • Fig. 11 Cellular starting materials market: Product movement analysis
  • Fig. 12 Leukopaks market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Cells & tissues market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Cellular starting materials market: Grade outlook and key takeaways
  • Fig. 15 Cellular starting materials market: Grade movement analysis
  • Fig. 16 GMP market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Research-use market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Cellular starting materials market: End use outlook and key takeaways
  • Fig. 19 Cellular starting materials market: End use movement analysis
  • Fig. 20 Pharmaceutical & biotechnology companies market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 21 CMOs & CROs market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 22 Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Global cellular starting materials market: Regional outlook and key takeaways
  • Fig. 24 Global cellular starting materials market: Regional movement analysis
  • Fig. 25 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Key country dynamics
  • Fig. 27 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Target Disease Prevalence
  • Fig. 29 Key country dynamics
  • Fig. 30 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Target Disease Prevalence
  • Fig. 32 Key country dynamics
  • Fig. 33 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Target Disease Prevalence
  • Fig. 35 Key country dynamics
  • Fig. 36 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Key country dynamics
  • Fig. 38 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Target Disease Prevalence
  • Fig. 40 Key country dynamics
  • Fig. 41 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Target Disease Prevalence
  • Fig. 43 Key country dynamics
  • Fig. 44 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Target Disease Prevalence
  • Fig. 46 Key country dynamics
  • Fig. 47 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Target Disease Prevalence
  • Fig. 49 Key country dynamics
  • Fig. 50 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Target Disease Prevalence
  • Fig. 52 Key country dynamics
  • Fig. 53 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Target Disease Prevalence
  • Fig. 55 Key country dynamics
  • Fig. 56 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Target Disease Prevalence
  • Fig. 58 Key country dynamics
  • Fig. 59 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Target Disease Prevalence
  • Fig. 61 Key country dynamics
  • Fig. 62 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Target Disease Prevalence
  • Fig. 66 Key country dynamics
  • Fig. 67 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Target Disease Prevalence
  • Fig. 69 Key country dynamics
  • Fig. 70 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Target Disease Prevalence
  • Fig. 72 Key country dynamics
  • Fig. 73 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Target Disease Prevalence
  • Fig. 75 Key country dynamics
  • Fig. 76 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Target Disease Prevalence
  • Fig. 78 Key country dynamics
  • Fig. 79 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Target Disease Prevalence
  • Fig. 81 Key country dynamics
  • Fig. 82 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Target Disease Prevalence
  • Fig. 86 Key country dynamics
  • Fig. 87 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Target Disease Prevalence
  • Fig. 89 Key country dynamics
  • Fig. 90 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Target Disease Prevalence
  • Fig. 94 Key country dynamics
  • Fig. 95 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Target Disease Prevalence
  • Fig. 97 Key country dynamics
  • Fig. 98 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Target Disease Prevalence
  • Fig. 100 Key country dynamics
  • Fig. 101 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Target Disease Prevalence
  • Fig. 103 Key country dynamics
目次
Product Code: GVR-4-68040-323-4

Cellular Starting Materials Market Growth & Trends:

The global cellular starting materials market size is anticipated to reach USD 4.84 billion by 2030, growingand is anticipated to expand at a CAGR of 22.74% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, rising investments, growing demand for cell and gene-based therapies, and technological innovations are expected to enhance the cellular starting materials market over the forecast period.

Cellular starting materials play a crucial role in supporting the development of cell and gene therapies. They are essential for both autologous and allogeneic cell therapies. As the field of cell therapy continues to expand rapidly, the demand for high-quality human cellular starting material is increasingincreases. Cell-based treatments are being investigated for a variety of conditions, including oncology, neurodegenerative disorders, and autoimmune diseases, leading to increased demand for different types of starting materials. Moreover, ongoing advancements in bioprocessing technologies, cell culture techniques, and quality control measures have enhanced the efficiency and scalability of manufacturing cellular starting materials, enabling companies to meet the increasing demand for these materials while maintaining product quality and consistency.

The COVID-19 pandemic had a significant impact onsignificantly impacted the market, with disruptions in supply chains and manufacturing processes leading to shortages and delays in manufacturing timelines. In the case of autologous cell therapies, the pandemic has caused extended patient collection times as patient-derived cells are used as starting material. However, the pandemic also underscored the importance of cell-based therapies and led to increased investments in the sector and accelerated regulatory approvals for some treatments.

However, strict regulations related to cell therapies present a major challenge to the cellular starting materials market. These regulations increase the costs of manufacturing cell and gene therapy products and obtaining the starting material. Various regions around the worldworldwide have established specific regulations governing the collection, processing, and use of cellular starting material for cell therapies. Cellular therapy products meeting specific criteria outlined in 21 CFR 1271.10(a) are regulated solely as Human Cells, Tissues, and Cellular and & Tissue-Based Products (HCT/Ps) under Section 361 of the Public Health Service Act of the U.S.

Cellular Starting Materials Market Report Highlights:

  • Leukopaks dominated the product segment with a market share of 70.80% in 2023, as they are essential cellular starting materials for cell-based therapies.
  • In 2023, GMP dominated the grade segment and held the largest market share in terms of revenue and is expected to grow at the highest CAGR of 22.78% over the forecast period.
  • Pharmaceutical and biotechnology companies dominated the end-use market with the largest share of 51.04% in 2023, driven by their significant investment in research and development to bring novel treatments to market, leveraging cellular starting materials as key components in their manufacturing processes.
  • Based on end use, tThe CMOs & CROs segment is anticipated to grow at the fastest CAGR due to their increasing adoption and investment in advanced research and manufacturing technologies.
  • The North American region dominated the cellular starting materials market with a share of 43.49% owing to factors such as increasing investments in R&D activities, rising demand for cell-based therapies, and advanced healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. Grade Segment
    • 1.2.3. End Use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Cellular Starting Materials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising demand for cell therapies
      • 3.2.1.2. Advancements in research and development for cell-based therapies
      • 3.2.1.3. Technological innovation
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost associated with the production and procurement of raw materials for cell therapies
      • 3.2.2.2. Stringent regulations associated with cell therapies
  • 3.3. Cellular Starting Materials Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Cellular Starting Materials Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Cellular Starting Materials Market Product Movement Analysis
  • 4.3. Global Cellular Starting Materials Market Size & Trend Analysis, by Product, 2018 - 2030 (USD Million)
  • 4.4. Leukopaks
    • 4.4.1. Leukopaks market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Cells & Tissues
    • 4.5.1. Cells & tissues market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Cellular Starting Materials Market: Grade Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Cellular Starting Materials Market Grade Movement Analysis
  • 5.3. Global Cellular Starting Materials Market Size & Trend Analysis, by Grade, 2018 - 2030 (USD Million)
  • 5.4. GMP
    • 5.4.1. GMP market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. Research-use
    • 5.5.1. Research-use market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Cellular Starting Materials Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Cellular Starting Materials Market End Use Movement Analysis
  • 6.3. Global Cellular Starting Materials Market Size & Trend Analysis, by End Use, 2018 - 2030 (USD Million)
  • 6.4. Pharmaceutical & Biotechnology Companies
    • 6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. CMOs & CROs
    • 6.5.1. CMOs & CROs market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Academic & Research Institutes
    • 6.6.1. Academic & research institutes market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Cellular Starting Materials Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 - 2030 (2018 - 2030)
  • 7.4. North America
    • 7.4.1. North America market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. Target disease prevalence
      • 7.4.2.5. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Target disease prevalence
      • 7.4.3.5. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. Target disease prevalence
      • 7.4.4.5. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Target disease prevalence
      • 7.5.2.5. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.3. UK
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Target disease prevalence
      • 7.5.3.5. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. Target disease prevalence
      • 7.5.4.5. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Target disease prevalence
      • 7.5.5.5. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Target disease prevalence
      • 7.5.6.5. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Target disease prevalence
      • 7.5.7.5. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Competitive scenario
      • 7.5.8.3. Regulatory framework
      • 7.5.8.4. Target disease prevalence
      • 7.5.8.5. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key country dynamics
      • 7.5.9.2. Competitive scenario
      • 7.5.9.3. Regulatory framework
      • 7.5.9.4. Target disease prevalence
      • 7.5.9.5. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Target disease prevalence
      • 7.6.2.5. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.3. Japan
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Target disease prevalence
      • 7.6.3.5. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Target disease prevalence
      • 7.6.4.5. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Target disease prevalence
      • 7.6.5.5. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Target disease prevalence
      • 7.6.6.5. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Competitive scenario
      • 7.6.7.3. Target disease prevalence
      • 7.6.7.4. Regulatory framework
      • 7.6.7.5. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Target disease prevalence
      • 7.7.2.5. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Target disease prevalence
      • 7.7.3.5. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Target disease prevalence
      • 7.8.2.5. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Competitive scenario
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. Target disease prevalence
      • 7.8.3.5. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Competitive scenario
      • 7.8.4.3. Regulatory framework
      • 7.8.4.4. Target disease prevalence
      • 7.8.4.5. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key country dynamics
      • 7.8.5.2. Competitive scenario
      • 7.8.5.3. Regulatory framework
      • 7.8.5.4. Target disease prevalence
      • 7.8.5.5. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. AllCells
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Charles River Laboratories
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. BioIVT
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. NMDP BioTherapies
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. CGT GLOBAL
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Excellos
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Anthony Nolan
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. STEMCELL Technologies
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. HumanCells Bio
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. AcceGen
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives